One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
ﻗﯿﻤﺖ : 300$- ﻗﯿﻤﺖ ﻭﯾﮋﻩ : 100$
Alzheimer's disease testing needs evidence, ethics, and equity
doi : 10.1016/S1474-4422(26)00324-8
Volume 25, Issue 10, October 2026
Charting the future of biomarkers and therapy in Alzheimer's disease
Third sector organisations unite to advance neuropalliative care
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Prevalence of unruptured intracranial aneurysms according to comorbidities, risk factors, country, and time period: a systematic review and meta-analysis
Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change
